Synmosa Biopharma Corp AI Stock Analysis
Synmosa Biopharma Corp (4114) AI Stock Analysis
Synmosa Biopharma Corp
(TPEx:4114)
Synmosa earns a moderate score. Its strongest attribute is a conservative, de-leveraged balance sheet alongside consistent revenue and earnings growth, supported by a fair 17.7x P/E and a 3.1% dividend yield. However, the score is held back by deteriorating cash generation — free cash flow fell roughly 75% and covered less than a third of net income — plus margin erosion versus 2022 and single-digit return on equity. Technicals add further pressure, with the share price below all key moving averages and a negative MACD, though extremely oversold momentum readings suggest downside may be nearing exhaustion. Low beta (0.31) limits volatility risk for income-oriented investors.
Synmosa Biopharma Corp (4114) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- TWD 15.04B
- Dividend Yield
- 3.05%
- Average Volume (3M)
- 842.05K
- Price to Earnings (P/E)
- 17.6
- Beta (1Y)
- 0.31
- Revenue Growth
- 11.40%
- EPS Growth
- 9.36%
- Country
- TW
- Employees
- 495
- Sector
- General
- Sector Strength
- 55
- Industry
- Drug Manufacturers - Specialty & Generic
Synmosa Biopharma Corp Business Overview & Revenue Model
Company Description
Synmosa Biopharma Corporation, established in Taipei, Taiwan, in 1980, operates as a dedicated specialty pharmaceutical enterprise. The company manages the entire lifecycle of pharmaceutical and healthcare products, from research and development to m...
Synmosa Biopharma Corp Financial Statement Overview
Summary
Solid fundamentals overall. Revenue has roughly doubled since 2020 to NT$6.19 billion, with net income up about 20% to NT$822 million and net margin improving to 13.3%. The balance sheet is a clear strength, with debt-to-equity cut to 0.29 and equity funding about 63% of assets, giving ample flexibility. Offsetting this, operating and EBITDA margins remain well below 2022 peaks, return on equity has slipped to about 9.4%, and cash conversion weakened sharply — free cash flow fell to NT$130 million, covering only about a third of reported profit.
Income Statement
73PositiveBalance Sheet
78PositiveCash Flow
46Neutral| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 6.68B | 6.19B | 5.55B | 5.14B | 4.39B | 3.23B |
| Gross Profit | 2.72B | 2.54B | 2.40B | 2.12B | 1.83B | 1.29B |
| EBITDA | 1.03B | 1.12B | 1.06B | 1.01B | 1.10B | 507.92M |
| Net Income | 775.69M | 821.85M | 684.68M | 594.83M | 799.09M | 303.86M |
Balance Sheet | ||||||
| Total Assets | 15.28B | 13.99B | 12.30B | 11.73B | 11.20B | 10.32B |
| Cash, Cash Equivalents and Short-Term Investments | 2.78B | 2.93B | 1.89B | 1.65B | 1.42B | 993.13M |
| Total Debt | 3.36B | 2.52B | 2.55B | 2.44B | 3.37B | 3.46B |
| Total Liabilities | 5.41B | 3.89B | 3.91B | 3.63B | 4.55B | 4.22B |
| Stockholders Equity | 8.65B | 8.76B | 7.21B | 6.71B | 5.31B | 4.71B |
Cash Flow | ||||||
| Free Cash Flow | 150.99M | 130.44M | 510.97M | 242.16M | 445.92M | 312.74M |
| Operating Cash Flow | 355.79M | 411.57M | 780.62M | 511.93M | 630.25M | 454.86M |
| Investing Cash Flow | -1.14B | -663.53M | -336.80M | -717.87M | -69.33M | 73.33M |
| Financing Cash Flow | 345.94M | 964.20M | -187.55M | 37.24M | -347.94M | -297.57M |
Synmosa Biopharma Corp Peers Comparison
Overall Rating
TW:662070Outperform- TW:411461Neutral
TW:178957Neutral
TW:414747Neutral
TW:654740Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| TW:6620 | 70Outperform | TWD 20.83B | 72.70 | ― | 1.65% | ― | ― |
| TW:4114 | 61Neutral | TWD 14.97B | 17.63 | ― | 3.05% | 11.40% | 9.36% |
| TW:1789 | 57Neutral | TWD 16.01B | 916.29 | ― | 1.43% | -4.75% | -90.91% |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| TW:4147 | 47Neutral | TWD 16.47B | -118.82 | ― | ― | 7.02% | 25.72% |
| TW:6547 | 40Underperform | TWD 16.94B | -408.17 | ― | ― | 44.37% | 78.11% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TW:4114 | Synmosa Biopharma Corp | 27.85 | -1.93 | -6.48% | |
| TW:1789 | Scinopharm Taiwan, Ltd. | 20.25 | 2.75 | 15.70% | |
| TW:4147 | TaiMed Biologics Inc. | 60.30 | -6.90 | -10.27% | |
| TW:6547 | Medigen Vaccine Biologics Corp. | 51.50 | 14.00 | 37.33% | |
| TW:6589 | EirGenix, Inc. | 51.40 | -16.40 | -24.19% | |
| TW:6620 | Handa Pharmaceuticals Inc | 125.50 | 6.46 | 5.43% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 09, 2026